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SUMMARY
With this Proposal we wish to replace the two previous proposals P42 and P48 
(corresponding to the ISOLDE Experiments ISC 330 and 331, respectively including 
the Addendum 1 dated 04.05.94.). Based on experimental results obtained during the 
last 4 year research in the frame work of the two proposals and considering modem 
trends in radiopharmaceutical developments we propose as a first main direction to 
study systematically relationships between physico-chemical parameters, the 
concentration and specific activity of tracer molecules and the corresponding biological 
response. This kind of studies requires highest achievable quality and a universality of 
radio-tracers, available at ISOLDE. Special attention in this concern is paid to bio­
specific tracers (receptor-binding ligands, bio-conjugates etc.) aiming to search for new 
and more efficient radiopharmaceuticals for radionuclide therapy. The second direction 
is to support clinical radionuclide therapy by a quantitative follow up of the 
radionuclide bio-distribution in vivo using PET (Positron emission tomography). 
ISOLDE produced positron emitting radionuclides (83Sr, 142Sm for example) are 
potential candidates for this kind of clinical research. A third direction is to evaluate the 
application of exotic radionuclides (as the alpha-emitting 149Tb) for radionuclide 
therapy.
1. Background:
1.1. Status of Nuclear Medicine
Nuclear Medicine is the application of radioactive tracers in vivo. The radioactive tracers used are 
named radiopharmaceuticals. Together with high technology imaging devices based on single photons 
or positron annihilation radiation we can obtain today detailed information on the function or 
malfunction of different metabolic processes in vivo with satisfactory high spatial resolution. Important 
aspects of research in radiopharmaceutical developments today are:
i. Increase specificity of functional imaging which requires radiotracers of new qualities, for
instance tracers of better specific activity or tracers labelled with new radio isotopes showing 
dedicated decay characteristics.
ii. Quantitation of nuclear medical imaging techniques is still an important question.
iii. The third aspect for research activities is the whole field of radiopharmaceuticals for therapy.
The above three mentioned aspects are subjects which can be significantly supported by using the 
radioactive ion beams produced at ISOLDE.
1.2. Special features of ISOLDE produced radio-tracers
There are three main aspects which makes ISOLDE produced radio-isotopes so valuable for use in bio­
medical research:
1. Availability of exotic or uncommon radio-isotopes: Spallation reaction makes available a 
complete range of isotopes having as complete a diversity of types and energies of radiation, 
of half-life, and of chemical properties as one would wish. Of special interest is the 
standardised availability of the full range of radio-lanthanides from just two standard ISOLDE 
target systems.
ii. High purity: The way of production guarantees that the radio-isotope preparations obtained 
at ISOLDE are really what we name carrier free preparations.
iii. Ion beam quality: The radioactive isotopes are obtained primarily as single charged ions 
of 60 keV energy. Thus, implantation may become an additional approach for new labelling 
technologies.
2. Bio-medical research based on radioactive ion beams at 
ISOLDE
2.1. Study of the relationships of bio-behaviour and specific activity
Radiopharmceuticals showing high functional specificity can not be used in unlimited concentration. 
The in vivo biodistribution and bio-kinetic behaviour very much depend on the concentration of binding 
sites in vivo. This is especially true for ligands binding to receptor. The concentration of receptors is 
limited. When the tracer concentration is too high all receptors are blocked. This may lead to wrong
diagnostic results, to misinterpretation of the result obtained, or can cause dangerous clinical syndromes. 
Therapeutic effects may be lost when carrier containing radiopharmceuticals are used. Especially in 
radionuclide therapy we are forced to use high specific activities to ensure that the radiotracer really is 
specifically adsorbed in the lesions selected for targeted therapy. Unfortunately, the radionuclides used in 
therapy often cannot be produced carrierfree using the classical production routes. Systematic studies are 
required to determine carefully the relationship between specific activity of the tracer and the biological 
response. For this aspect clearly carrierfree radionuclides are required.
We propose to use ISOLDE produced radioisotopes in this field:
2.1.1. ISOLDE produced 153Sm in 153Sm EDTMP therapy
153Sm is commercially produced via 152Sm (n,g) 153Sm reaction in nuclear reactors. Consequently the 
specific activity is limited and depends on neutron flux density available, the enrichment of the target 
material and the duration of activation. The precise knowledge about the influence of the specific 
activity on the biokinetic and biodistribution will help to optimise the therapy. In previous studies we 
measured carefully the relationship between EDTMP-ligand concentration and biokinetic behaviour of 
carrier free radio-lanthanides [1]. From Fig.l we learnt that the ligand concentration plays an extremely 
important role when low molecular chelators are used as ligands. We propose now to perform similar 
biokinetic studies using well defined specific activities of the radio-lanthanides with special emphasis to 
153Sm. A similar experimental design is proposed for 83Sr as well as outlined below under Top.2.3.
2.1.2. Radio-lanthanides for labelling of bioconjugates
Bioconjugates are molecules which consist of a protein or peptide conjugated with a bifunctional ligand. 
The basic molecule contains a specific bioselective function which usually determines the biokinetic 
behaviour. The bifunctional ligand consists of a linker molecule and a chelator. The function is to 
connect a radioactive isotope stable to the basic molecule or body. The concentration of binding sites in 
vivo are usually very limited. Consequently we should bring only the same or even a lower number of 
labelled molecules as tracer into the body in order to achieve maximum effect. The whole field suffers 
form the limited availability of high quality absolutely carrierfree radionuclides which can be used. 
ISOLDE produced radio-lanthanides are ideal for this kind of studies. In our earlier experiments (IS 
330) we could demonstrate that monoclonal antibodies as well as Octreotides can be successfully labelled 
with any of the radio-lanthanides available at ISOLDE [2,3] (Fig.2 and Fig.3)
This field is advancing well.
i. In the case of monoclonal antibodies a new technique “bifunctional monoclonal antibodies” is 
under development. The principle is to create new “receptor” binding sites in vivo which show higher 
binding affinity to small molecules which are then labelled with a radio-tracer. Due to the smaller 
molecule size the biokinetics becomes faster and highe tumor to tissue ratios are obtained. More
convenience for clinical application is expected. ISOLDE produced radio-lanthanides are ideal radio­
tracers for this kind of systematic studies.
ii. It has been proposed to use fragments of monoclonal antibodies (fab) [6] only. The fragments 
carry the full bio-selective information of the mab but they are much smaller molecules. Because of the 
smaller size fab's show a faster clearance. All approaches to adapt radioactive metal ions to proteins 
(bifunctional ligands) can be used for fab's as well. We plan to use ISOLDE produced radio-lanthanides 
for this kind of systematic study.
iii. Low molecular weight peptides are intensely investigated concerning their potential for 
diagnosis and therapy (see for instance [4]). Thus, Octreotide, a somatostatine analogue consisting of 8 
aminoacids, can be labelled with lanthanides via a bifunctional ligand. Since the receptor concentration 
in vivo is limited only Octreotides of high specific activity can show a better tumor accumulation. 
Presently, intense research activity is directed to modify the molecule with the aim to improve the organ 
distribution. ISOLDE produced carrier free radioactive metal ions will definitely support this 
developments of new and more efficient types of radionuclide therapy.
2.1.3. Relationship between biokinetic behaviour and chelate stability
As mentioned above and written in the previous proposals a suitable chelating group plays an important 
role in biocojugates. Generally we wish to use the monoclonal antibodies or receptor binding molecules 
as carrier or vehicle to transport selectively a radioisotope into tumor cells. Suitable isotopes of 
therapeutic interest are usually b' emitter, difficult to obtain in the required high quality. In addition 
different chelating groups may be possible. Different linker molecules carrying polyamino- 
poly carboxy lie acid groups have been proposed as chelators. The trend goes to chelating groups 
providing highest possible complex stability constants. DTPA is a chelator which provides satisfactory 
high complex formation stability constants for a wide range of metal ions, including the lanthanides. 
Complex formation is very fast and easy. Higher complex stability is obtained with DOTA, a cyclic 
chelator. However, the complex formation requires usually stronger conditions (increased temperature 
and time). If the chelate complex stability is unsatisfactorily low, then a dissociation in vivo would form 
free unchelated radiolabelled species which follow their own biodistribution. From our preliminary 
studies we learnt that the liver is the critical organ. This is the case for 225-Ac labelled benzylamino- 
DTPA monoclonal antibodies (Fig.2), while for yttrium or heavy lanthanides a partial dissociation of the 
complex compound would be less critically, because the liver accumulation of those ionic species is 
relatively low. However, in case of yttrium instead of the liver the bone uptake may now become 
critically. It is assumed that DTPA derivatised at the carbone backbone in the linker molecule provides 
satisfactory complex stability for most of the lanthanides and yttrium (Fig.3). We propose to perform 
systematic studies in order to establish clear relationship between the chelate complex stability and the 
biological behaviour. Radio-lanthanides, produced at ISOLDE are the most ideal instrument for this 
kind of study. The tracers are carrierfree and we can change the stability constant without any changes
in the basic molecule. Reference nuclides as 1HIn and 67Ga as well as other metallic radionuclides as 
radio-yttrium and actinium will be included in this systematic study.
From our systematic biokinetic studies involving DTPA-, DOT A- and other chelating groups in peptides 
(such as Octreotide) in combination with ISOLDE produced radio-lanthanides, Ga, In and Cu we expect 
more and complete information on the influence of the complex stability and the biokinetic behaviour 
The answer to this question will help to make better and more efficient radiopharmaceuticals for 
therapy.
2  2  149x5 a suitable radionuclide for radionulide therapy
Cancer proceeds through a number of quite separate stages in the development of lethal disease. Early 
stages offer the potential for control if alpha emitting radioimmunotherapy (RIT) is applied. Later stages 
may be more appropriate for beta RIT. Prophylactic therapy of metastatic cancer requires the localisation 
of dose to the cancer cell and rules out radioactive beta emitting radionuclides. Alpha emitting nuclides, 
however, are much more appropriate toxins, as their efficacy depends on the energy and the range of the 
alpha particles emitted.
The lethal dose for subclinical lesions of 10^ cells is 20 Gy. In order to limit the systemic dose to 2 Gy to 
the body, a 10:1 tumor to tissue dose ratio is required. For 100 cancer cells in circulation only 10 Gy and 
a 5:1 dose ratio is required. But for beta therapy, only 2.5 % of the beta energy is deposited in a cancer 
cell with 1311, so only 1:40 dose ratio is achievable. Thus control of isolated cells is not efficient because 
there is a 5 x 50 = 200 fold short fall in dose ratio and beta radionuclides therapy cannot reasonably be 
expected to control cancer cells ore small cancer cell clusters. Alpha particles have higher linear energy 
transfer (LET) than betas, so fewer hits are required to kill a cell. The short range of alpha means much 
lower dose to surrounding normal cells if a tracer molecule with cancer specific properties (such as mab) 
is used. Cross fire is not an important aspect of dose delivery as it is with betas and microdosimetry 
calculations are required to determine median cell dose and cell survival probabilities.
Among the existing alpha emitters the 149Tb turns out to be the most promising candidate for RIT 
because of the low energy of the alpha particles emitted. Presently the ISOLDE facility is the only 
facility where this isotope is available in the required quantity (0.5-1 GBq) and quality (carrier-free) [5]. 
The half life of 149Tb is very much shorter than that of beta-emitting isotopes used in radionuclide 
therapy today. As monoclonal antibodies may take as long as 24 - 48 hours to reach peak uptake in solid 
tumors, such tumors are not the target for 149Tb alpha radionuclide therapy. Uptake times required for 
cell in transit or pre-angeogenic lesions are expected to be very short, and such, the short half-life of 
149Tb may be of advantage. Thus, the alpha emitting 149Tb offers a more enlightened approach to the 
control of early stages cancer or leukaemia.
The following experiments based on l49Tb are planned:
* cell culture uptake studies
* cell culture surviving experiments
* animal survival studies
* phantom PET studies to learn about feasibility of quantitation using positron 
branching in the 149Tb decay.
ISOLDE is so far the only facility in the world where we have access to 149Tb in the required amount 
and quality.
2.3. Quantitation using positron emitters
This aspect is related to clinical tasks. Radionuclide therapy (RIT) aims to bring selectively radioactive 
isotopes into tumor cells and deposit locally a high rediation dose without damaging the surrounding 
healthy tissue. With two exception (131I as iodide and 89Sr as Sr2+) one needs the help of biospecific 
carrier molecules which carry the radiotracer into the target cell. As outlined above suitable carriers are 
monoclonal antibodies, fragments, peptides or even low molecular weight chelating ligands. One of the 
problems today is the fact that we cannot measure the individual regional uptake of the therapeutic 
tracer in vivo, thus we can not determine the real dose deposited in a target region. Consequently one 
can not establish clear relationship between a deposited radiation dose and the corresonding response. In 
order to answer this question we need an individual quantitation of the tracer concentration in regions of 
interest in vivo. Positron emission tomography (PET) is the only technique today, which allows to 
determine absolute radioactivity concentration in vivo. Using positron emitting isotopes of the same 
element which is used in therapy we are really able to quantify the uptake and determine deposited 
doses. Suitable candidates to perform such in vivo dosimetry are for example 83Sr, 86Y, 142Sm. The 83Sr 
(Tl/2=32.4 h) is a suitable positron emitter which can be used to monitor the 89Sr uptake in bone 
metastasis in palliative pain therapy. The 86Y (Tl/2=14.7 h) has been proposed to do the same when 90Y 
CITRATE or 90Y EDTMP is used. In our previous Proposal we demonstrated that ISOLDE produced 
142Sm provides excellent PET images and consequently 142Sm is a suitable positron emitter to monitor 
153Sm. We propose to support both, the 89Sr and 153Sm EDTMP radionuclide therapy with clinical PET 
studies based on 83Sr and 142Sm. Both positron emitters are available at ISOLDE in excellent quality 
and quantities.
3. Beam time request
The isotopes of interest along this proposal are produced using mainly three ISOLDE targets (in 
combination with the hot surface ionisation ion source):
Nb-foil target (83.82Sr; 86,85y)
Ta-foil target and (radio-lanthanides)
(or combined Nb-foil / Ta-foil target)
U-carbide (neutron rich light radio-lanthanides, 225Ra)
In contrast to usual proposals we are able to plan our experiments according to the beam time schedule 
relatively flexible. Usually we need for the experiments between 1 0 ^  and 1 0 ^  collected atoms 
depending on the half life of the nuclide. This can be usually achieved during 1/2 - 2 shifts collection 
dme. The collection of A=225 from U-carbide requires minimum 4 shifts.





A combined Ta-Nb foil target is welcome, increases flexibility and enables us to have more frequendy 
access to ISOLDE beams.
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Fig-1
Tumor to liver ratio of radionuclide uptake for radio-lanthanides and 225Ac 
in tumor bearing mice as function of the EDTMP ligand concentration.
We learn that with increased ligand concentration the tumor to liver ratio can change 
dramatically by a factor 50 due to a reduction o f the liver uptake. The ratio obtained for 
the heavy lanthanides (167Tm as a representative) is around 10 and decreases with 
growing ionic radius to about 2 for Sm, 0.7 for Ce to 0.3 for Ac. The radio-tracers used 
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Fig.2
Tumor uptake of monoclonal antibodies labelled with 152(}d, 169Yb, 141Ce 
and 225 Ac (carrier-free, produced at the ISOLDE facility at CERN) and 
m In (purchased from Amersham) in tumor bearing nude mice.
No differences can be seen between behaviour of the radio-lanthanides and UIIn 
labelled mab. However, the low and decreasing with time tumor uptake in case of 225Ac 
is explained by the far insufficient stability of the Ac-DTPA complex binding.
Chelators with significant higher stability constants are required for this element. For 














80 85 90 95 100 105 110 115
Fig.3 ¡onic radius in pm
Comparison of the biokinetic behaviour of succinylaminobenzyl-DTPA- 
Octreotide and aminobenzyl-DTPA monoclonal antibodies labelled with 
111In, radio-lanthanides and 225Ac.
The tumor liver ratio of tracer uptake is plotted versus the ionic radius of the metallic 
radionuclide. With the Octreotide generally significant higher tumor to liver ratios are 
obtained. For ions smaller than Pm no differences in the biokinetic behaviour can be 
detected. For the lanthanides below Pm and Ac the ratios value fall down because of a 
decreased in vivo stability indicating insufficient chelate complex stability. For more 
details see [2 and 3].

